Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

InspireMD (NSPR) Research & Development (2016 - 2025)

InspireMD's Research & Development history spans 16 years, with the latest figure at $3.5 million for Q4 2025.

  • For Q4 2025, Research & Development fell 5.9% year-over-year to $3.5 million; the TTM value through Dec 2025 reached $15.0 million, up 10.04%, while the annual FY2025 figure was $15.0 million, 10.04% up from the prior year.
  • Research & Development reached $3.5 million in Q4 2025 per NSPR's latest filing, down from $3.6 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $4.1 million in Q1 2025 to a low of $839000.0 in Q1 2021.
  • Average Research & Development over 5 years is $2.5 million, with a median of $2.1 million recorded in 2022.
  • Peak YoY movement for Research & Development: soared 190.54% in 2021, then dropped 7.15% in 2025.
  • A 5-year view of Research & Development shows it stood at $1.5 million in 2021, then surged by 31.23% to $2.0 million in 2022, then grew by 1.09% to $2.0 million in 2023, then skyrocketed by 81.47% to $3.7 million in 2024, then dropped by 5.9% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for NSPR's Research & Development are $3.5 million (Q4 2025), $3.6 million (Q3 2025), and $3.8 million (Q2 2025).